Yu-Kai Su

Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages

Hao-Yu Chuang, Yu-Kai Su, Heng-Wei Liu et al. · Journal of Clinical Medicine · 2019 · 88 citations · Full text

Medicine, Oncology, Pharmacology +17

Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver

Yu-Kai Su, Rosewell V. Mackey, Ahsun Riaz et al. · Journal of Vascular and Interventional Radiology · 2017 · 75 citations

Medicine, Nuclear Medicine, Oncology +16

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes

Wei Li, Yu-Kai Su, Chien‐Min Lin et al. · Oncotarget · 2016 · 59 citations · Full text

Medicine, Oncology, Pharmacology +17

Analysis of the RENAL and mRENAL Scores and the Relative Importance of Their Components in the Prediction of Complications and Local Progression after Percutaneous Renal Cryoablation

S. Mouli, Joseph McDevitt, Yu-Kai Su et al. · Journal of Vascular and Interventional Radiology · 2017 · 36 citations

Medicine, Nephrology, Surgery +13

Ovatodiolide inhibits the oncogenicity and cancer stem cell-like phenotype of glioblastoma cells, as well as potentiate the anticancer effect of temozolomide

Yu-Kai Su, Oluwaseun Adebayo Bamodu, Yew‐Min Tzeng et al. · Phytomedicine · 2019 · 34 citations

Medicine, Oncology, Pharmacology +15